Generate Biomedicines (NASDAQ:GENB) Coverage Initiated by Analysts at HC Wainwright

Key Points

• HC Wainwright initiated coverage with a buy rating and a $16.00 price target, implying roughly a 40% upside from the recent close.
• Six analysts currently have Buy ratings and one has a Hold, leaving an average consensus of Moderate Buy with an average target price of $23.20.
• Generate Biomedicines is a biotech that uses machine learning and generative AI to design novel therapeutics; GENB opened at $11.41 and is trading near its 52‑week low of $11.00 (52‑week high $15.32).

HC Wainwright began coverage on shares of Generate Biomedicines (NASDAQ:GENB - Get Free Report) in a report released on Monday,Benzinga reports. The firm set a "buy" rating and a $16.00 price target on the stock. HC Wainwright's target price points to a potential upside of 40.23% from the stock's previous close.

GENB has been the subject of a number of other reports. Guggenheim began coverage on shares of Generate Biomedicines in a report on Tuesday, March 24th. They issued a "buy" rating and a $30.00 price target for the company. Wall Street Zen raised shares of Generate Biomedicines to a "hold" rating in a report on Saturday, March 14th. Cantor Fitzgerald began coverage on shares of Generate Biomedicines in a report on Tuesday, March 24th. They issued an "overweight" rating for the company. Zacks Research raised shares of Generate Biomedicines to a "hold" rating in a report on Wednesday, March 25th. Finally, Piper Sandler began coverage on shares of Generate Biomedicines in a report on Tuesday, March 24th. They issued an "overweight" rating and a $24.00 price target for the company. Six investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $23.20.

Generate Biomedicines Stock Performance

GENB stock opened at $11.41 on Monday. Generate Biomedicines has a fifty-two week low of $11.00 and a fifty-two week high of $15.32.

About Generate Biomedicines

Generate Biomedicines, Inc NASDAQ: GENB is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.